公司简介

InSilico Medicine Hong Kong Limited

Insilico Medicine developed an AI platform which allows for rapid identification of new molecular targets using multi-omics data and rapid generation of novel compounds using AI. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Technology Innovation Award. The company is betting on the innovative pharmaceutical industry in Greater China and established the HQ in Hong Kong and R&D offices in Taipei. It has a close collaboration with the greatest research platform, WuXi AppTec on synthetic chemistry. Its goal is to help the Chinese pharmaceutical companies leapfrog years of pharmaceutical R&D using next-generation AI and provide novel disease-relevant targets and novel small molecules for these targets. This strategy is aligned with the new policy of the Chinese government intended to foster and promote the creation of innovative medicine in China. Pandomics.com Insilico Medicine developed Pandomics, a bioinformatics and AI platform which allows for rapid identification of new molecular targets using multi-omics data and rapid generation of novel compounds using AI - https://pandomics.com/

Unit 307A, Core Building 1, No. 1 Science Park East Avenue, Pak Shek Kok, Hong Kong Science Park, Hong Kong
+852 2360 0139
Ms. Teresa Leung

以上资料仅供参考。有关园区公司的最新资讯,请以其官方公布的讯息为准。

联系我们

如有一般咨询,或有关香港科技园服务与援助计划的问题,请在下方空白处填写您的电子邮箱和咨询内容。